Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
According to a story from Cure Today, the biopharmaceutical company Ambrx Biopharma, Inc., recently announced that the US Food and Drug Administration (FDA) has given Fast Track designation to the…
Results of a recent study published in Medscape Medical News assessed the effect of treatment with radiotherapy on patients who have prostate cancer that is localized. Statistics show that…
Researchers have uncovered a new way to treat cancer that could lessen the side effects that patients often experience from chemotherapy. At the same time, it improves the curative power…
According to Newswise, the FDA recently approved a new prostate cancer imaging technique developed by researchers at UCLA and UCSF. The imaging technique, called prostate-specific membrane antigen PET imaging (PSMA…
A recent article in Cure Today describes the impact of a new class of injectable radiation therapy on Barbara Davis’ metastatic breast cancer and Dr. Howard Schiff’s metastatic prostate…
Merck and AstraZeneca recently announced that Lynparza improved overall survival in the lives of males with advanced prostate cancer who had been treated previously. The drug out-performed two other antiandrogen…
The term ‘failure’ may no longer apply to cancer vaccines according to a recent article in Marketwatch. Researchers have endured over four decades of frustration since the first two…
.jpg)
490 words 8% vs 1306 words 3% According to a recent Globe Newswire release, Progenics Pharmaceuticals, an oncology company that specializes in artificial intelligence and targeted therapies, announced results for its Phase…
According to a press release from American pharmaceutical giant Pfizer, Inc. the FDA recently agreed to review a supplemental New Drug Application for Xtandi. Xtandi was first approved for the…
According to a story from WebMD, a recent study revealed that men with Crohn's disease, ulcerative colitis, or other forms of inflammatory bowel disease are at an increased risk of…
An enormous anonymous donation of more than $18 million has been given to the BC Cancer Foundation to fund cutting-edge treatments. The news was announced in an article by the…
Results from a study that were presented at the European Society for Medical Oncology’s Congress have shown that the investigational drug for prostate cancer INO-5150 may be able to slow…
LiPlaCis is a formulation of cisplatin that delivers its agent directly to cancerous tumor sites. Its efficacy has so far only been studied within breast cancer patients. However, scientists have reason to…
Top-line data from a Phase 3 study of an experimental method of visualising prostate cancer has been announced. While it met the primary endpoint for specificity, it did not meet…
According to The Guardian, some researchers believe that the term "cancer" should be omitted from some medical diagnoses. Among these diagnoses include those for small thyroid cancer, low and intermediate…
A study of Lynparza (olaparib) in combination with abiraterone for the treatment of metastatic castration-resistant prostate cancer has shown promising results. The full article can be read here, at Bio…
A drug to treat prostate cancer has been approved by the US Food and Drug Administration. The drug, Xtandi ® (enzalutamide), had previously been approved for castration-resistant prostate cancer (CRPC)…
According to a story from Jewish Community Voice, the BRCA Founder Outreach Study, which is a national, cancer-focused research study, is offering free screenings for people of Ashkenazi Jewish descent.…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
